Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 1.00 |
| ▸ | SENP1 | Q9P0U3 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 4/20 | 0.73 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.73 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.73 |
| ▸ | PTPRF | P10586 | 3/20 | 0.73 |
| ▸ | CES1 | P23141 | 3/20 | 0.73 |
| ▸ | ACP1 | P24666 | 3/20 | 0.73 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.73 |
| ▸ | RELA | Q04206 | 3/20 | 0.73 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.73 |
| ▸ | USP7 | Q93009 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | USP2 | O75604 | 2/20 | 0.73 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.73 |
| ▸ | CTSD | P07339 | 1/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.73 |
| ▸ | CETP | P11597 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pomolic Acid SCHEMBL7357945 | 1.00 | PTPN1 (1.00) | PTPN1SENP1POLBPTPN2AKR1B10 | |
| Pomolic Acid SCHEMBL7035935 | 1.00 | PTPN1 (1.00) | PTPN1SENP1POLBPTPN2AKR1B10 | |
| Pomolic Acid SCHEMBL30417300 | 1.00 | PTPN1 (1.00) | PTPN1SENP1POLBPTPN2AKR1B10 | |
| Epipomolic Acid SCHEMBL7035933 | 1.00 | PTPN1 (1.00) | PTPN1SENP1POLBPTPN2AKR1B10 | |
| Pomolic Acid SCHEMBL7357947 | 1.00 | PTPN1 (1.00) | PTPN1SENP1POLBPTPN2AKR1B10 | |
| Pomolic Acid SCHEMBL12181563 | 1.00 | PTPN1 (1.00) | PTPN1SENP1POLBPTPN2AKR1B10 | |
| Pomolic Acid SCHEMBL1049001 | 1.00 | PTPN1 (1.00) | PTPN1SENP1POLBPTPN2AKR1B10 | |
| Pomolic Acid SCHEMBL20971332 | 1.00 | PTPN1 (1.00) | PTPN1SENP1POLBPTPN2AKR1B10 | |
| Pomolic Acid SCHEMBL20998163 | 1.00 | PTPN1 (1.00) | PTPN1SENP1POLBPTPN2AKR1B10 | |
| Pomolic Acid SCHEMBL1049053 | 1.00 | PTPN1 (1.00) | PTPN1SENP1POLBPTPN2AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486457-B2 | Compositions that treat or inhibit pathological conditions associated with inflammatory response | METAPROTEOMICS, LLC. (US) | 2013-07-16 | — | — | US | claimed |
| US-7790205-B2 | Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response | METAPROTEOMICS, LLC (US) | 2010-09-07 | — | — | US | claimed |
| US-7431948-B2 | Compositions that treat or inhibit pathological conditions associated with inflammatory response | METAPROTEOMICS, LLC (US) | 2008-10-07 | — | — | US | claimed |
| US-7270835-B2 | Compositions that treat or inhibit pathological conditions associated with inflammatory response | METAPROTEOMICS, LLC (US) | 2007-09-18 | — | — | US | claimed |
| US-20070184133-A1 | Compositions that treat or inhibit pathological conditions associated with inflammatory response | METAPROTEOMICS, LLC (US) | 2007-08-09 | — | — | US | claimed |
| US-20070160692-A1 | Compositions that treat or inhibit pathological conditions associated with inflammatory response | META PROTEOMICS, LLC | 2007-07-12 | — | — | US | claimed |
| US-20060177531-A1 | Compositions that treat or inhibit pathological conditions associated with inflammatory response | META PROTEOMICS, LLC | 2006-08-10 | — | — | US | claimed |
| US-20060127513-A1 | Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-06-15 | — | — | US | claimed |
| US-20060127517-A1 | Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response | META PROTEOMICS, LLC | 2006-06-15 | — | — | US | claimed |
| EP-1558271-A4 | COMPOSITIONS THAT TREAT OR INHIBIT PATHOLOGICAL CONDITIONS ASSOCIATED WITH INFLAMMATORY RESPONSE | METAPROTEOMICS LLC (US) | 2006-01-11 | — | — | EP | claimed |
| EP-1558271-A2 | COMPOSITIONS THAT TREAT OR INHIBIT PATHOLOGICAL CONDITIONS ASSOCIATED WITH INFLAMMATORY RESPONSE | Metaproteomics, LLC (US) | 2005-08-03 | — | — | EP | claimed |
| US-20040151792-A1 | Compositions that treat or inhibit pathological conditions associated with inflammatory response | FORTRESS CREDIT CORP. (AS COLLATERAL AGENT) | 2004-08-05 | — | — | US | claimed |
| WO-2004037180-A2 | COMPOSITIONS THAT TREAT OR INHIBIT PATHOLOGICAL CONDITIONS ASSOCIATED WITH INFLAMMATORY RESPONSE | METAPROTEOMICS, LLC (US) | 2004-05-06 | — | — | WO | claimed |
| US-20040086580-A1 | Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response | META PROTEOMICS, LLC | 2004-05-06 | — | — | US | claimed |
| US-11026897-B2 | Composition of curcumagalactomannoside and hops extract | METAGENICS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200046651-A1 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2020-02-13 | — | — | US | disclosed |
| US-RE46276-E1 | Triazolo(4,5-D)pyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2017-01-17 | — | — | US | disclosed |
| EP-1386909-A1 | Cyclopropane amines | AstraZeneca AB (SE) | 2004-02-04 | — | — | EP | disclosed |
| EP-1386921-A1 | Intermediates | AstraZeneca AB (SE) | 2004-02-04 | — | — | EP | disclosed |
| US-6525060-B1 | P2T (P2YADP or P2TAC) receptor antagonists; anticoagulant, antithrombotic | ASTRAZENECA UK LIMITED (GB) | 2003-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060177531-A1 | Compositions that treat or inhibit pathological conditions associated with inflammatory response | HPGDS, TPSB2, HMGB2 | PTPN1 808/4885SENP1 2604/4885POLB 4111/4885 |
| US-20040086580-A1 | Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response | HPGDS, TPSB2, TPSG1 | PTPN1 791/4885SENP1 2460/4885POLB 4246/4885 |
| US-20070184133-A1 | Compositions that treat or inhibit pathological conditions associated with inflammatory response | HPGDS, TPSB2, HMGB2 | PTPN1 808/4885SENP1 2604/4885POLB 4111/4885 |
| US-20040151792-A1 | Compositions that treat or inhibit pathological conditions associated with inflammatory response | HPGDS, TPSB2, HMGB2 | PTPN1 808/4885SENP1 2604/4885POLB 4111/4885 |
| US-20060127513-A1 | Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response | HPGDS, TPSB2, TPSG1 | PTPN1 791/4885SENP1 2460/4885POLB 4246/4885 |
| US-20060127517-A1 | Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response | HPGDS, TPSB2, TPSG1 | PTPN1 791/4885SENP1 2460/4885POLB 4246/4885 |
| US-11026897-B2 | Composition of curcumagalactomannoside and hops extract | HMGB1, CHIT1, NOD2 | PTPN1 464/4885SENP1 3625/4885POLB 3937/4885 |
| US-20200046651-A1 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE | NOD2, NLRP1, NOD1 | PTPN1 665/4885SENP1 3522/4885POLB 3175/4885 |
| US-20070160692-A1 | Compositions that treat or inhibit pathological conditions associated with inflammatory response | HPGDS, TPSB2, HMGB2 | PTPN1 808/4885SENP1 2604/4885POLB 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.